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Background-—Information is scarce regarding effects of antihypertensive medication on blood pressure variability (BPV) and
associated clinical outcomes. We examined whether antihypertensive treatment changes BPV over time and whether such change
(decline or increase) has any association with long-term mortality in an elderly hypertensive population.
Methods and Results-—We used data from a subset of participants in the Second Australian National Blood Pressure study (n=496)
aged ≥65 years who had 24-hour ambulatory blood pressure recordings at study entry (baseline) and then after a median of 2 years
while on treatment (follow-up). Weighted day-night systolic BPV was calculated for both baseline and follow-up as a weighted mean of
daytime and nighttime blood pressure standard deviations. The annual rate of change in BPV over time was calculated from these BPV
estimates. Furthermore, we classified both BPV estimates as high and low based on the baseline median BPV value and then classified
BPV changes into stable: low BPV, stable: high BPV, decline: high to low, and increase: low to high. We observed an annual decline
(meanSD: 0.371.95; 95% CI, 0.54 to 0.19; P<0.001) in weighted day-night systolic BPV between baseline and follow-up.
Having constant stable: high BPV was associated with an increase in all-cause mortality (hazard ratio: 3.03; 95% CI, 1.67–5.52) and
cardiovascular mortality (hazard ratio: 3.70; 95% CI, 1.62–8.47) in relation to the stable: low BPV group over a median 8.6 years after
the follow-up ambulatory blood pressure monitoring. Similarly, higher risk was observed in the decline: high to low group.
Conclusions-—Our results demonstrate that in elderly hypertensive patients, average BPV declined over 2 years of follow-up after
initiation of antihypertensive therapy, and having higher BPV (regardless of any change) was associated with increased long-term
mortality. ( J Am Heart Assoc. 2019;8:e012630. DOI: 10.1161/JAHA.119.012630.)
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B lood pressure variability (BPV) has been identified as apotential target for management of hypertension because
BPV appears to be associated with hypertension-associated
organ damage and is a predictor of future cardiovascular events
regardless of age.1–4 However, findings regarding the relation-
ship between BPV and clinical outcomes have not been
consistent.5–7 BPV is defined as the variation between multiple
blood pressure (BP) records obtained from either ambulatory or
visit-to-visit (ie, same clinic visit or between different clinic
visits) BP records for an individual. BPV estimated from either
visit-to-visit or ambulatory BP (ABP) records has been associ-
ated with increased cardiovascular risk.3,8,9
We recently reported that BPV estimated using ABP
monitoring (ABPM) performs better in future cardiovascular
risk prediction compared with BPV estimated from clinic
visit-to-visit BP records (from the same participants).10
Because ABPM estimates BPV over a short period of time,
it overcomes the lack of consensus on the requirements for
the number of clinic visits for BPV measurement and the
time interval between clinic visits to estimate visit-to-visit
BPV.11 We also reported that among the different ABPM
estimates of BPV, weighted day-night and daytime systolic
BP (SBP) variability perform better for predicting future all-
cause and cardiovascular mortality compared with 24-hour
and nighttime BPV.10
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Evidence from preclinical and clinical studies suggests
that use of antihypertensive therapy could reduce BPV, and
this treatment-related reduction of BPV may contribute to
cardiovascular protection.12–14 To our knowledge, no infor-
mation is available on the relationship between reducing BPV
by using BP-lowering medication and long-term clinical
outcomes.
In this study, we conducted a post hoc analysis with the
aim of evaluating the effect of BP-lowering treatment on
systolic BPV (SBPV) estimated from ABPM recordings in an
elderly hypertensive Australian population. We also explored
whether any change in ambulatory SBPV (ASBPV) had an
association with all-cause and cardiovascular mortality out-
comes over long-term follow-up.
Methods
The data that support the findings of this study are available
from the ANBP2 (Second Australian National Blood Pressure
Study) Management Committee on reasonable request (con-
tact C.M.R., christopher.reid@curtin.edu.au).
Study Settings
We used data from a subgroup of participants in ANBP2 who
were aged ≥65 years (at enrollment) and who participated in
the ABP substudy (n=735). ANBP2 was a prospective
randomized open-label trial with blinded assessment of end
points. The protocols for both the main study and the ABP
substudy were approved by the ethics committee of the Royal
Australian College of General Practitioners and conducted in
accordance with the Helsinki Declaration of the World Medical
Association. All participants gave written informed consent.
ANBP2 was conducted with 6083 elderly hypertensive
participants during 1995–2001 in 1594 family medical
practices from 5 Australian states. The primary aim of the
study was to compare the outcome of treatment using a BP-
lowering drug regimen based on either a diuretic or an
angiotensin-converting enzyme inhibitor in these elderly
hypertensive participants. Details about the study design,
treatments, results, and recruitment processes were pub-
lished previously.15,16 After the end of the ANBP2 clinical trial
(median: 4.1 years), a further follow-up for a total of
11 years was conducted to determine participants’ survival
status. In this current analysis, we included only the ABP
substudy participants who had completed a “successful” 24-
hour ABP recording at study entry (baseline, pretreatment)
and then again after a median of 2 years while on treatment
(follow-up).
BP Measurement and BPV
ABP was measured at baseline before the commencement of
randomized antihypertensive treatment and then again during
the clinical trial period after a median of 2 years after
randomization into the study. ABP recordings were made with
a Spacelabs 90207 portable noninvasive device (Spacelabs
Healthcare) using an appropriately sized cuff. During ABP
measurement, SBP and diastolic BP were recorded at 30-
minute intervals throughout a 26-hour recording period. Only
the BP measurements made from 2 to 26 hours on each
ambulatory record were considered for this analysis. A
successful recording was defined as having ≥80% technically
satisfactory readings (ie, ≥38 readings) over the 2- to 26-hour
recording period.
We previously demonstrated that weighted day-night SBPV
avoids the confounding effect of nocturnal BP reduction and
the morning rise in BP and has been shown to correlate
better with survival (all-cause and cardiovascular mortality)10
and end-organ damage17 in relation to 24-hour BPV; there-
fore, we used this approach as the measure of SBPV in the
current analysis. To estimate SBPV, we applied the same
procedure for the baseline (pretreatment) and follow-up (on
treatment) BP records. Briefly, SBPV for an individual
participant was initially measured as the standard deviation
of SBP between readings for the separate daytime and
nighttime BP records. Time definitions have been used to
define the day period (10 AM to 8 PM) and the night period (12
AM to 6 AM).17 Then we calculated weighted day-night ASBPV
from the mean of day and night SBPV corrected for the time
Clinical Perspective
What Is New?
• This study examines whether blood pressure variability
(BPV) changes following initiation of antihypertensive treat-
ment in an elderly hypertensive population.
• The study examines the association of changes (increase or
decrease) in BPV with long-term survival.
What Are the Clinical Implications?
• Higher ambulatory systolic BPV estimated from ambulatory
blood pressure recordings (either pretreatment or while on
treatment) is a strong predictor of cardiovascular and all-
cause mortality.
• Treating elderly hypertensive patients with antihypertensive
therapy could reduce blood pressure as well as ambulatory
systolic BPV.
• Presence of high systolic BPV, which is defined as having
systolic BPV above the baseline median level, regardless of
whether levels remain high or decline during the follow-up
period was associated with increased mortality during long-
term follow-up.
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interval in each observed period (day-night) using the
following equation: [{(daytime SD910)+(nighttime SD96)}/
16].18
Change in SBPV
The annual rate of change in weighted day-night ASBPV
(between baseline and follow-up) was calculated from these
SBPV estimates. Furthermore, we classified both ASBPV
estimates as high or low based on the baseline median ASBPV
value because there is no agreed cutoff point to define high
SBPV; then we classified ASBPV changes in relation to
baseline into stable: low BPV, stable: high BPV, decline: high to
low, or increase: low to high.
Follow-Up and End Points
The association of weighted day-night SBPV changes with
mortality was assessed over a median of 8.6 years
(interquartile range: 8.0–9.2 years) after the follow-up
ABPM during the clinical trial period until data were
censored at October 31, 2009. This follow-up period
includes part of the ANBP2 clinical trial period (median:
2.1 years) together with a posttrial follow-up period
(median: 6.9 years; Figure 1). During the clinical trial
period, a blinded independent end point committee adjudi-
cated all study end points, including causes of death.
Posttrial survival information was determined by linkage to
the Australian Institute of Health and Welfare National
Death Index (death registry). International Classification of
Diseases, Tenth Revision (ICD-10) coding was used to
identify cause of death. For the purpose of the current
study, we used all-cause mortality and cardiovascular
mortality (composed of sudden cardiac death, fatal stroke,
fatal myocardial infarction, and “other” cardiovascular
causes of death) as end points.
Statistical Analyses
Statistical analyses were performed based on the intention-to-
treat principle using Stata v15.1 for Windows (StataCorp). We
summarized the baseline and on-treatment demographic and
clinical characteristics of the participants overall and com-
pared them across the classifications based on ASBPV
changes in relation to baseline (stable: low BPV, stable: high
BPV, decline: high to low and increase: low to high).
Continuous variables were compared using ANOVA, and
categorical variables were compared using v2 tests in relation
to those who experienced stable: low BPV over the follow-up
time. Thereafter, we used Cox proportional hazards models to
explore the effects of in-trial changes in ASBPV (weighted day-
night) on all-cause and cardiovascular mortality using the
subgroup observed as stable: low BPV as the comparator. For
this analysis, we used each participant’s follow-up ABPM
measurement date as his or her observation start time and
that participant’s data were censored at October 31, 2009, or
earlier if he or she died. The Cox proportional hazards model
was adjusted for each participant’s baseline characteristics
such as age, sex, smoking and alcohol drinking status,
previous history of cardiovascular disease, renal function
(based on estimated glomerular filtration rate calculated using
the CKD-EPI [Chronic Kidney Disease Epidemiology Collabo-
ration] equation), diabetes mellitus, plasma total and HDL
(high-density lipoprotein) cholesterol concentrations, physical
activity, and mean ASBP at baseline. In addition, in-trial
randomized treatment group (angiotensin-converting enzyme
inhibitor/diuretics) and number of antihypertensive drugs
used by each participant were included because these
variables showed strong associations with ≥1 end point in
the current analysis or in earlier published papers.19 Further-
more, we conducted regression analysis to identify the factors
associated with changes in ASBPV. We used simple linear
regression analyses to identify the baseline and in-trial
characteristics (Table 1) that showed an association with
median 2 y
ANBP2 clinical trial
(median 4.1 years)
ANBP2 extended follow-up
(median 6.9 years)
Randomization
ANBP2
end point
Follow-up 
end point
ABPM
Baseline In-trial     (at least one)
Follow-up and Outcome ascertainment
Long-term Follow-up after last ABPM
Figure 1. Overview of ANBP2 (Second Australian National Blood Pressure Study) and long-term follow-up,
ABPM (ambulatory blood pressure monitoring), clinical outcome ascertainment, and analysis time periods.
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Table 1. BP at Baseline and During Follow-Up Period Along With Corresponding Changes and Distribution of Baseline
Characteristics of the ANBP2 ABPM Substudy Participants Overall and Categorized by Weighted Day-Night SBPV Change
During in-trial Follow-Up
Overall (N=496)
Stable: Low BPV
(n=185, 37.3%)
Stable: High BPV
(n=131, 26.4%)
Decline: High to
Low (n=117, 23.6%)
Increase: Low to
High (n=63, 12.7%)
ASBP and variability
At baseline
Daytime SBP 15615 15013 16216* 15714* 15916*
Nighttime SBP 13716 13213 14319* 13715* 13815*
24-h SBP 14914 14412 15515* 14913* 15114*
Pulse pressure, 24 h 6612 6110 7113* 6711* 6511*
Weighted day-night BPV 11.842.91 9.361.44 14.582.44* 13.661.54* 10.061.00*
At follow-up
Daytime SBP 14215 13813 14716* 13814 14715*
Nighttime SBP 12615 12213 13116* 12414 12917*
24-h SBP 13614 13212 14214* 13413 14015*
Pulse pressure, 24 h 6111 5710 6512* 6111* 6210*
Weighted day-night BPV 11.243.16 9.021.47 14.712.65* 9.501.20* 13.742.01*
Change in SBP and variability
Daytime SBP 1415 1312 1517 1816* 1113
Nighttime SBP 1114 1012 1217 1313 913
24-h SBP 1313 1111 1315 1613* 1111
Pulse pressure, 24 h 58 56 610 78* 36
Weighted day-night BPV 0.603.28 0.341.89 0.133.11 4.161.87* 3.652.20*
Annual change in ASBPV,
meanSD (95% CI)
0.371.95
(0.54 to 0.19)
0.211.08
(0.5 to 0.37)
0.091.88
(0.24 to 0.41)
2.421.28*
(2.65 to 2.18)
2.041.41*
(1.68–2.39)
Baseline characteristics
Age, y, meanSD 71.44.6 70.54.4 73.04.9* 71.34.6 71.04.4
≥75 y, %) 26.4 20.5 36.6* 26.5 22.2
Male, % 56.9 62.7 54.2 44.4* 68.3
Education, %
Primary 9.7 6.5 9.2 15.4* 9.5
Some high school 44.0 48.1 39.7 41.9* 44.4
Completed high school/university 46.4 45.4 51.2 42.7* 46.0
Regional location, % 0.8 1.1 0.0 0.9 1.6
BMI, kg/m2, meanSD 27.03.7 27.03.2 26.43.7 27.13.9 27.74.3
Obese (BMI ≥30), % 19.8 15.7 17.6 27.4* 22.2
Current smoker, % 5.0 2.7 8.4* 1.7 11.1*
Current drinker, % 79.2 74.6 84.0* 74.4 92.1*
Previous antihypertensive therapy, % 68.5 65.9 66.4 77.8* 63.5
Previous CVD, % 11.7 9.7 17.6* 10.3 7.9
Diabetes mellitus 6.0 4.3 8.4 6.0 6.3
Depression 4.8 3.2 9.2* 4.3 1.6
Raised cholesterol (>6.5 mmol/L), % 20.6 22.7 21.5 19.7 14.5
Low HDL (<1 mmol/L), % 12.5 14.8 9.3 9.6 17.7
Continued
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change in ASBPV. Those variables that showed an association
(P<0.10) with change in ASBPV were included in a multinomial
linear regression model to identify the determinants of change
in ASBPV.
Results
Of those who participated in the ANBP2 ambulatory substudy,
702 (of 735) had successful baseline (prerandomization) ABP
records and 515 (of 538 with follow-up ABP records) had
successful follow-up (on treatment) ABP records. In total, 496
participants had successful ABP records for both baseline and
follow-up. The average 24-hour ABP (systolic/diastolic) for
participants at baseline was 149/83 mm Hg and during
follow-up was 136/76 mm Hg. Average ASBP over 24 hours,
during day and nighttime; estimated weighted day-night
ASBPV at baseline and follow-up; and changes between
follow-up and baseline values are summarized in Table 1.
Change in ASBPV
Among the study participants we observed a decline in
weighted day-night ASBPV (meanSD: 0.603.28
mm Hg; 95% CI, 0.89 to 0.31; P<0.001) over a median
of 2 years of follow-up (interquartile range: 1.9–2.1 years).
We observed that the change in ASBPV was positively
associated with change in SBP between baseline and follow-
up ABPM (Figure 2).The observed annual rate of decline of
weighted day-night ASBPV was 0.371.95 mm Hg (95% CI,
0.54 to0.19). We used the baseline median weighted SBPV
(11.59 mm Hg) to classify baseline and follow-up ASBPV as low
or high and then changes in ASBPV as stable: low BPV, stable:
high BPV, decline: high to low, or increase: low to high. Overall,
63% retained a similar level of ASBPV (stable, high or low) at
baseline and during in-trail follow-up (37% had stable: low BPV
and 26% had stable: high BPV), whereas 24% had decline: high
to low and 13% had increase: low to high ASBPV while on
antihypertensive medication.
Table 1 summarizes the weighted day-night ASBPV,
changes in ASBPV and the corresponding baseline and in-trial
demographic and clinical characteristics of the participants
according to classified groups based on changes in ASBPV.
Compared with the stable: low BPV group, we observed higher
ASBP and weighted 24-hour ASBPV at baseline and during the
follow-up period in the other 3 groups (stable: high BPV, decline:
Table 1. Continued
Overall (N=496)
Stable: Low BPV
(n=185, 37.3%)
Stable: High BPV
(n=131, 26.4%)
Decline: High to
Low (n=117, 23.6%)
Increase: Low to
High (n=63, 12.7%)
eGFR, mL/min/1.73 m2, meanSD 68.913.5 70.714.0 67.614.0 67.212.1* 69.612.9
Physical activities in previous 2 wk, %
No exercise 26.6 31.3 25.9* 22.2* 22.2
1–6 h 28.4 33.0 19.9* 26.5* 36.5
≥7 h 45.0 35.7 54.2* 51.3* 41.3
In-trial characteristics
Randomized to receive ACEI, % 49.2 51.9 48.9 42.7 54.0
No. of antihypertensives
1 50.0 54.6 49.6 43.6* 49.2
≥2 46.0 39.5 48.1 53.8* 46.0
No drug 4.0 5.9 2.3 2.6* 4.8
ABPM indicates ambulatory blood pressure monitoring; ACEI, angiotensin-converting enzyme inhibitor; ANBP2, Second Australian National Blood Pressure Study; ASBP, ambulatory systolic
blood pressure; ASBPV, ambulatory systolic blood pressure variability; BMI, body mass index; BP, blood pressure; BPV, blood pressure variability; CVD, cardiovascular disease; eGFR,
estimated glomerular filtration rate; HDL, high-density lipoprotein; SBP, systolic blood pressure; SBPV, systolic blood pressure variability.
*Significant differences (P<0.05) with those observed as stable: low BPV.
Figure 2. Association between weighted day-night ASBP
change and ASBP variability change. ASBP indicates ambulatory
systolic blood pressure; SBP, systolic blood pressure.
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high to low and increase: low to high), except for follow-up ASBP
of the decline: high to low group (Table 1). We observed that the
participants who experienced a decline in ASBPV from baseline
to follow-up (decline: high to low group), compared with the
stable: low BPV group, were mostly female, were obese, had
previous history of treatment with an antihypertensive, were
physically active at baseline, and had been using multiple
antihypertensive medications (independent of the randomiza-
tion treatment group) during the follow-up period. In addition at
baseline, compared with the stable: low BPV group, those who
had stable: high BPV were mostly older, had previous history of
cardiovascular disease, were more likely to be active smokers
and alcohol drinkers, and those who had increase: low to high
ASBPV were more likely to be active smokers and alcohol
drinkers.
Relationship Between Change in ASBPV and
Mortality
Among the study participants there were 96 deaths (23.8 per
1000 person-years) from any cause over a median of 8.6
years (interquartile range: 8.0–9.2 years) following the last
ABP measurement. Of these 96 deaths, 49 deaths (12.2 per
1000 person-years) were of cardiovascular origin. We
observed that increases per millimeters of mercury in
weighted day-night ASBPV at both baseline and follow-up
were significant predictors of all-cause and cardiovascular
mortality independent of baseline SBP (Table 2). However, we
did not observe any significant association of mortality
(hazard ratio, all-cause: 0.98 [95% CI, 0.88–1.09]; P=0.74;
cardiovascular: 0.95 [95% CI, 0.82–1.10]; P=0.46) with
change in weighed day-night SBPV (per mm Hg) over time.
We observed significantly higher risk of all-cause and
cardiovascular mortality in those who had high ASBPV at
baseline (either stable: high BPV or decline: high to low
groups) compared with those who had constant low weighed
day-night ASBPV (stable: low BPV; Table 3). There was no
significant difference in mortality among participants who had
low ASBPV at baseline but had an increase in ASBPV later
during the follow-up period (increase: low to high group)
Table 2. Association of Baseline and Follow-Up Weighted
Day-Night SBPV (per mm Hg Increase) With Mortality
SBPV
All-Cause Mortality,
HR (95% CI)
Cardiovascular Mortality,
HR (95% CI)
At baseline
Model 1 1.20 (1.12–1.28), P<0.001 1.26 (1.15–1.39), P<0.001
Model 2 1.19 (1.10–1.28), P<0.001 1.24 (1.12–1.36), P<0.001
At follow-up
Model 1 1.12 (1.05–1.19), P<0.001 1.15 (1.05–1.25), P=0.002
Model 2 1.11 (1.04–1.18), P=0.002 1.11 (1.02–1.22), P=0.017
Model 1: HR adjusted for age, sex, smoking, drinking, history of previous heart disease,
diabetes, raised cholesterol, low HDL (high-density lipoprotein) cholesterol, and
estimated glomerular filtration rate at baseline and in-trial use of either angiotensin-
converting enzyme inhibitors or diuretics and number of antihypertensive drugs. Model
2: model 1 adjusted for corresponding mean ambulatory systolic blood pressure
(baseline/follow-up). HR indicates hazard ratio; SBPV, systolic blood pressure variability.
Table 3. Effect of Change in SBPV on All-Cause and Cardiovascular Mortality in Relation to Those With Stable: Low BPV
BPV indicates blood pressure variability; HR, hazard ratio; SBPV, systolic blood pressure variability.
*HR adjusted for age, sex, smoking, drinking, history of previous heart disease, diabetes mellitus, mean ambulatory systolic blood pressure, raised cholesterol, low HDL (high-density
lipoprotein) cholesterol, and estimated glomerular filtration rate at baseline and use of either angiotensin-converting enzyme inhibitor or diuretics and number of antihypertensive drugs
during the ANBP2 (Second Australian National Blood Pressure Study) trial period.
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compared with those who had stable low ASBPV (stable: low
BPV group; Table 3). The mortality incidence curves for all-
cause and cardiovascular mortality by ASBPV change status
(stable: low BPV, stable: high BPV, decline: high to low and
increase: low to high) over the follow-up period are shown in
Figure 3. A restricted analysis was conducted among the
participants who had higher ASBPV at baseline to assess any
beneficial effect of ASBPV lowering in the decline: high to low
group in relation to those with stable: high BPV. We did not
observe any significant difference in mortality risk between
these 2 groups (Figure 4).
Determinants of ASBPV Change During the Trial
Period
The results of the simple linear regression analysis of variables
from the baseline and follow-up periods that could have an
association with change in ASBPV are presented in Table 4. In the
multinomial linear regressionmodel (which included only variables
that showed an association of P<0.10 in Table 4), we observed
that change inweightedday-nightASBPVover the follow-upperiod
was related positively to change in 24-hour ASBP, tomale sex, and
to being an active smoker at baseline (Table 5).
Discussion
We demonstrated in our elderly hypertensive cohort that
treatment with BP-lowering medication was associated with
reduction in ASBPV, expressed as weighted day-night ASBPV.
We also showed that having baseline ASBPV above the
median regardless of any change over the follow-up period
had an increased risk of all-cause and cardiovascular mortality
compared with those who had below-median ASBPV at
Figure 3. Incidence of all-cause mortality (A) and cardiovascular mortality (B) following last ABPM by ambulatory
systolic BPV change status among treated hypertensive patients. ABPM indicates ambulatory blood pressure monitoring;
BPV, blood pressure variability.
Figure 4. Survival by ambulatory systolic BPV change
among treated hypertensive patients with high BPV at
baseline for all-cause mortality (A) and cardiovascular
mortality (B) following last ABPM. ABPM indicates ambu-
latory blood pressure monitoring; BPV, blood pressure
variability; HR, hazard ratio.
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baseline, independent of other risk factors for higher mortal-
ity. The latter is a novel finding.
Use of antihypertensive medications has been observed to
be associated with decreased ASBPV based on 24-hour ABPM
in earlier studies,14,20 and the reduction of BPV has been shown
to be positively correlated to reduction in BP.14 During the in-
trial period of our study, over a median 2 years following the
baseline ABP measurement, we also observed a small but
statistically significant annual decline in weighted ASBPV
(0.37 mm Hg) among the treated hypertensive study partici-
pants, and the reduction in ASBPV was positively correlated
with lowering of BP. These findings suggest that changing SBPV
is largely dependent on the change in SBP. Although use of
multiple antihypertensive drugs was previously reported to be
associated with changes in BPV,20 we did not observe any such
association.We also did not observe any difference in the role of
the different randomized drug-treatment regimens (based on
angiotensin-converting enzyme inhibitor or thiazide diuretic) on
ASBPV. Our relatively small sample size and the small number of
people taking multiple antihypertensive medications in our
study may be the underlying reasons for not confirming the
previous observation. We also observed that male participants,
active smokers, and active alcohol drinkers had higher SBPV.
In our study, the changes we observed in BPV over follow-
up after introduction of BP-lowering treatment were reduction
in ASBPV (decline: high to low) in 24% of the participants and
Table 4. Association of Different Baseline and In-Trial Factors With Change in ASBPV in Simple Linear Regression Analysis
Coefficient
95% Confidence Interval
P ValueLower Upper
Change in 24-h SBP (per mm Hg/y) 0.06 0.03 0.08 <0.001
Age 75 y or more (vs <75 y) 0.08 0.47 0.31 0.67
Male (vs female) 0.53 0.19 0.88 0.003
Previous history of heart disease 0.18 0.72 0.35 0.50
Previous history of antihypertensive use 0.25 0.62 0.12 0.19
eGFR (per mL/min/1.73 m2) 0.01 0.005 0.02 0.23
Low HDL 0.30 0.22 0.83 0.26
Raised cholesterol 0.10 0.53 0.32 0.64
Active smoker 1.01 0.23 1.79 0.01
Active drinker 0.53 0.11 0.95 0.01
Diabetes mellitus 0.05 0.67 0.77 0.90
Depression 0.42 1.23 0.38 0.30
Exercise in previous 2 wk
None Ref
1–6 h 0.14 0.60 0.33 0.56
≥7 h 0.09 0.51 0.33 0.68
ACEI (vs diuretic) 0.30 0.04 0.65 0.08
No. of BP-lowering medications used
1 Ref
≥2 0.13 0.49 0.22 0.45
None 0.06 0.95 0.83 0.90
ACEI indicates angiotensin-converting enzyme inhibitor; ASBPV, ambulatory systolic blood pressure variability; BP, blood pressure; eGFR, estimated glomerular filtration rate; HDL, high-
density lipoprotein; Ref, referent; SBP, systolic blood pressure.
Table 5. Determinants of Change in ASBPV in a Multinomial
Linear Regression Model
Coefficient (95% CI) P Value
Change in 24-h SBP
(per mm Hg/y)
0.06 (0.03–0.08) <0.001
Male (vs female) 0.44 (0.10–0.78) 0.01
Active smoker 1.06 (0.29–1.81) 0.01
Active drinker 0.39 (0.03 to 0.80) 0.07
ACEI (vs diuretic) 0.17 (0.16 to 0.50) 0.32
ACEI indicates angiotensin-converting enzyme inhibitor; ASBPV, ambulatory systolic
blood pressure variability; SBP, systolic blood pressure.
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rise in ASBPV (increase: low to high) in 13% of the participants
compared with ASBPV status at baseline. The remaining 63% of
participants had no change in ASBPV despite also using BP-
lowering medication. During the follow-up period, higher all-
cause and cardiovascular mortality was observed among those
who had constant higher ASBPV (stable: high BPV) or who
experienced reduction in ASBPV from high baseline to low
(decline: high to low) compared with those who had constant
low ASBPV (stable: low BPV). Consequently, in the current
analysis, lowering higher ASBPV did not have any significant
beneficial effect on lowering of mortality risk. In addition, those
who were observed to have an increase in ASBPV from low
ASBPV at baseline did not experience any significant increase
in mortality risk. To our knowledge, no other study to date has
reported the associations we have described.
Our study has several limitations. First, for each individual
participant, we used only one 24-hour ABP recording at
baseline and one during follow-up. However, we observed that
higher SBPV measured both at baseline and follow-up could
predict mortality outcome. Second, we did not have data on
participants’ BP and BPV status and antihypertensive medica-
tion use during the extended follow-up time after the formal
clinical trial had been completed, which might have affected
the association of change in BPV with the long-term outcome of
interest, namely, mortality. Furthermore, we could not explore
the effect of the use of additional individual drug classes (eg, b-
blockers or calcium channel blockers) on BPV because, for the
majority of participants, information on the duration (ie, start
and/or end date) of additional drug use was inadequate. Third,
the number of participants included in the current analysis is
relatively small, possibly leading to a type II error. However, this
study is one of the first to assess the relationship of survival
and BPV change over time, in our case in elderly hypertensive
participants. Fourth, we did not consider participants’ chronic
pain, anxiety, or other factors that might have affected change
in BPV. Fifth, we used standard deviations to estimate BPV
instead of other measures. In an earlier study conducted in the
same population, we found that BPV estimated using standard
deviation performed similarly to or better than other BPV
estimation techniques.1 Furthermore, in various population-
based studies, standard deviation of 24-hour BP has frequently
been reported to demonstrate an association with cardiovas-
cular events and mortality.8,21,22 Last, ANBP2 was conducted
in elderly hypertensive people treated in the context of a
clinical trial; therefore, the findings from this present study may
not be applicable to other age groups or settings.
Conclusions
This study presents the factors associated with changes in
ASBPV among elderly hypertensive people over time and the
relationship of changes in ASBPV to mortality in these people.
In this study we observed that treating elderly hypertensive
people with BP-lowering drugs reduced BP and ASBPV. We
observed that the presence of high BPV (ie, BPV above the
baseline median level regardless of whether levels remain
high or decline during follow-up) was associated with
increased mortality over long-term follow-up. A reduction in
ASBPV while on BP-lowering treatment did not lower the risk
of mortality. Those who were most at risk of higher mortality
associated with higher baseline ASBPV were typically older,
had previous history of cardiovascular disease, and were more
likely to be active smokers and alcohol drinkers. Our results
fill the information gap regarding the relationship of BPV and
changes associated with BP-lowering treatment to subse-
quent mortality. Our results suggest that further research is
needed with larger sample sizes and other population groups
to confirm or refute our findings that reducing BPV with BP-
lowering treatment does not alter subsequent outcome.
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